Gilead Sciences, Inc. (GILD)
NASDAQ · Healthcare · Drug Manufacturers - General
Profile
Gilead Sciences, Inc.
- Exchange
- NASDAQ
- Ticker
- GILD
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Country
- US
Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets. Its core mission involves discovering, developing, and commercializing innovative medications to address critical health needs. The company's extensive product portfolio encompasses treatments for a variety of severe conditions. For HIV/AIDS, it supplies key therapies such as Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. In response to the 2019 coronavirus pandemic, Gilead provides Veklury, an injectable drug for intravenous administration. Its offerings for liver diseases include Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. Furthermore, Gilead assists patients battling hematological disorders, various cancers, and those undergoing cell therapy, through products like Yescarta, Tecartus, Trodelvy, and Zydelig. Other specialized medicines include Letairis, an oral drug for pulmonary arterial hypertension; Ranexa, also an oral medication, for chronic angina; and AmBisome, a liposomal formulation designed to combat serious invasive fungal infections. Gilead Sciences, Inc. actively engages in collaboration agreements with a diverse range of partners to advance its therapeutic pipeline. These include Arcus Biosciences, Inc., Pionyr Immunotherapeutics Inc., Tizona Therapeutics, Inc., Tango Therapeutics, Inc., Jounce Therapeutics, Inc., Galapagos NV, Janssen Sciences Ireland Unlimited Company, Japan Tobacco, Inc., Gadeta B.V., Bristol-Myers Squibb Company, Dragonfly Therapeutics, Inc., and Merck & Co, Inc. The company was founded in 1987 and its corporate headquarters are situated in Foster City, California.
Key facts
Gilead Sciences, Inc.: key facts
- Gilead Sciences, Inc. (NASDAQ: GILD) is a Drug Manufacturers - General company in the Healthcare sector.
- In fiscal 2025, Gilead Sciences, Inc. reported revenue of $29.4B and net income of $8.5B.
- Revenue grew 1.9% a year over the last 4 fiscal years.
- Free cash flow was positive in 5 of the last 5 fiscal years.
- Net income was positive in 5 of the last 5 fiscal years.
- Over the last twelve months, revenue was $31.0B and net income was -$3.9B.
MonkScore
Gilead Sciences, Inc.'s MonkScore
MonkScore
MonkScore range: 90–100
as of October 2026
Sector rank: 39 of 628 in Healthcare
How this score is madeDisclaimer
Pillar ranges
- Growth40–50
- Profitability50–60
- Quality90–100
- Market Conviction90–100
- Safety90–100
The MonkScore runs from 0 to 100. Each range is one of ten 10-point groups, from 0–10 to 90–100.
Each pillar's range uses the same ten groups. The exact score and the pillar scores are in the MonkStreet app.
Fundamentals
Figures from the statements
Gilead Sciences, Inc.'s annual figures and the last twelve months, in USD. Last report: 30 September 2026.
| Figure | Last 12 months | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Revenue | $31.0B | $29.4B | $28.8B | $27.1B | $27.3B | $27.3B |
| Gross profit | $24.8B | $23.2B | $22.5B | $20.6B | $21.6B | $20.7B |
| Operating income | -$1.4B | $11.7B | $1.7B | $7.6B | $7.3B | $9.9B |
| Net income | -$3.9B | $8.5B | $480.0M | $5.7B | $4.6B | $6.2B |
| Operating cash flow | $14.5B | $10.0B | $10.8B | $8.0B | $9.1B | $11.4B |
| Capital expenditure | -$442.0M | -$563.0M | -$523.0M | -$585.0M | -$728.0M | -$579.0M |
| Free cash flow | $14.0B | $9.5B | $10.3B | $7.4B | $8.3B | $10.8B |
| Total debt | $26.2B | $24.9B | $26.7B | $25.0B | $25.2B | $26.7B |
| Cash | $6.4B | $7.6B | $10.0B | $6.1B | $5.4B | $5.3B |
Revenue growth a year
- 1-year
- 2.4%
- 3-year
- 2.6%
- 4-year
- 1.9%
Compound growth between fiscal years.
Score my top stocks · 14-day free trial · card required · not charged during the trial · cancel in one click
MonkStreet provides research, not investment advice.
Page built on 31 October 2026.